OMS-527 is under clinical development by Omeros and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect OMS-527’s likelihood of approval (LoA) and phase transition for Binge Eating Disorder took place on 02 Nov 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their OMS-527 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
OMS-527 is under development for the treatment of movement disorders such as Parkinson's disease, restless legs syndrome, compulsive disorders and for nicotine, cocaine, opioid and alcohol addiction as well as for binge eating disorder. The drug candidate targets phosphodiesterases 7 (PDE7).
Omeros is a biopharmaceutical company that discovers, develops and commercializes small-molecule and protein therapeutics for large-market and orphan indications. The company’s marketed product, Omidria is a phenylephrine and ketorolac injection for use during cataract surgery or replacement of intraocular lens (IOL). The company is investigating its product candidates for use in arthroscopic, ophthalmological, and other surgical procedures including thrombotic microangiopathies, mediated glomerulopathies, addictive and compulsive disorders among others. It is also evaluating preclinical product candidates for treatment of alternative pathway disorders, central nervous system disorders, metabolic, oncologic, musculoskeletal and other disorders. Omeros is headquartered in Seattle, Washington, the US.
Quick View OMS-527 LOA Data
|Highest Development Stage|